{"id":"flag-ida","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FLAG-IDA combines fludarabine (a purine analog), cytarabine (a pyrimidine analog), and idarubicin (a topoisomerase II inhibitor) to target leukemic cells through multiple mechanisms. Fludarabine and cytarabine interfere with DNA synthesis, while idarubicin intercalates DNA and inhibits topoisomerase II, leading to cell death. This combination is particularly effective in hematologic malignancies with high proliferation rates.","oneSentence":"FLAG-IDA is a combination chemotherapy regimen that inhibits DNA synthesis and promotes apoptosis in rapidly dividing cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:47.106Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML), relapsed or refractory"},{"name":"Acute lymphoblastic leukemia (ALL), relapsed or refractory"}]},"trialDetails":[{"nctId":"NCT06713837","phase":"PHASE3","title":"IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2025-02-27","conditions":"Acute Myeloid Leukemia, Relapse/Recurrence","enrollment":339},{"nctId":"NCT04375631","phase":"PHASE1","title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-03","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome","enrollment":120},{"nctId":"NCT03214562","phase":"PHASE1, PHASE2","title":"Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-09-26","conditions":"High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":116},{"nctId":"NCT06034470","phase":"PHASE1","title":"Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2023-12-18","conditions":"Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome","enrollment":30},{"nctId":"NCT07046078","phase":"PHASE2","title":"Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-26","conditions":"Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":20},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT07228273","phase":"PHASE2","title":"Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-12-12","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":102},{"nctId":"NCT07297173","phase":"PHASE1","title":"Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-12-01","conditions":"Relapsed Leukemia, Refractory Leukemia","enrollment":5},{"nctId":"NCT02421939","phase":"PHASE3","title":"A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2015-10-20","conditions":"Leukemia, Acute Myeloid (AML)","enrollment":371},{"nctId":"NCT06001788","phase":"PHASE1","title":"Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2024-02-22","conditions":"AML, AML With Mutated NPM1, Hematologic Malignancy","enrollment":171},{"nctId":"NCT06928662","phase":"PHASE1, PHASE2","title":"Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-23","conditions":"Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia","enrollment":36},{"nctId":"NCT06387069","phase":"PHASE3","title":"A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Hutchmed","startDate":"2024-04-26","conditions":"Acute Myeloid Leukemia","enrollment":316},{"nctId":"NCT05586074","phase":"PHASE3","title":"HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML","status":"RECRUITING","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2023-03-03","conditions":"Leukemia, Acute Myeloid (AML)","enrollment":324},{"nctId":"NCT02920008","phase":"PHASE3","title":"Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2017-03-16","conditions":"Acute Myeloid Leukemia","enrollment":302},{"nctId":"NCT02400281","phase":"PHASE1, PHASE2","title":"Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients","status":"COMPLETED","sponsor":"Arog Pharmaceuticals, Inc.","startDate":"2015-09","conditions":"Acute Myeloid Leukemia","enrollment":28},{"nctId":"NCT06418776","phase":"PHASE3","title":"IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML","status":"RECRUITING","sponsor":"National Research Center for Hematology, Russia","startDate":"2024-04-01","conditions":"Refractory Acute Myeloid Leukemia, Early Relapses of Acute Myeloid Leukemia","enrollment":198},{"nctId":"NCT02013167","phase":"PHASE3","title":"Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Amgen","startDate":"2014-01-03","conditions":"Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia","enrollment":405},{"nctId":"NCT04112589","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2019-12-26","conditions":"Acute Myeloid Leukemia","enrollment":63},{"nctId":"NCT03257241","phase":"PHASE3","title":"A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old","status":"UNKNOWN","sponsor":"Polish Adult Leukemia Group","startDate":"2017-07-03","conditions":"Acute Myeloid Leukemia","enrollment":582},{"nctId":"NCT03250338","phase":"PHASE3","title":"Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML","status":"UNKNOWN","sponsor":"Arog Pharmaceuticals, Inc.","startDate":"2018-06-05","conditions":"Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations","enrollment":322},{"nctId":"NCT02039726","phase":"PHASE3","title":"(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2014-05","conditions":"AML","enrollment":367},{"nctId":"NCT03661515","phase":"PHASE1","title":"Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2018-07-17","conditions":"Acute Myeloid Leukemia","enrollment":16},{"nctId":"NCT02272478","phase":"PHASE2, PHASE3","title":"Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations","status":"UNKNOWN","sponsor":"Cardiff University","startDate":"2014-10-30","conditions":"Acute Myeloid Leukaemia, Myelodysplastic Syndrome","enrollment":1600},{"nctId":"NCT03446638","phase":"NA","title":"iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2019-05","conditions":"Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT01496547","phase":"PHASE2","title":"Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse AML","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2011-01","conditions":"Acute Leukemia","enrollment":47},{"nctId":"NCT02844530","phase":"PHASE2","title":"Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL","status":"WITHDRAWN","sponsor":"Nantes University Hospital","startDate":"","conditions":"CD22+ Relapsed/Refractory B-ALL","enrollment":""},{"nctId":"NCT00651781","phase":"PHASE1, PHASE2","title":"Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2008-04","conditions":"Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT00487448","phase":"PHASE4","title":"SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"1998-07","conditions":"Myelodysplastic Syndrome, Acute Myeloblastic Leukemia","enrollment":200},{"nctId":"NCT00559221","phase":"PHASE2","title":"FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML","status":"UNKNOWN","sponsor":"Cooperative Study Group A for Hematology","startDate":"2004-12","conditions":"Acute Myeloid Leukemia","enrollment":37}],"_emaApprovals":[],"_faersSignals":[{"count":6,"reaction":"OFF LABEL USE"},{"count":5,"reaction":"DRUG INEFFECTIVE"},{"count":4,"reaction":"ACUTE MYELOID LEUKAEMIA RECURRENT"},{"count":4,"reaction":"DEATH"},{"count":4,"reaction":"PYREXIA"},{"count":3,"reaction":"ACUTE LYMPHOCYTIC LEUKAEMIA"},{"count":3,"reaction":"FEBRILE NEUTROPENIA"},{"count":2,"reaction":"ACUTE LYMPHOCYTIC LEUKAEMIA RECURRENT"},{"count":2,"reaction":"ACUTE MYELOID LEUKAEMIA"},{"count":2,"reaction":"HEPATIC FAILURE"}],"_approvalHistory":[],"publicationCount":105,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin"],"phase":"phase_3","status":"active","brandName":"FLAG-IDA","genericName":"FLAG-IDA","companyName":"Sunshine Lake Pharma Co., Ltd.","companyId":"sunshine-lake-pharma-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FLAG-IDA is a combination chemotherapy regimen that inhibits DNA synthesis and promotes apoptosis in rapidly dividing cells. Used for Acute myeloid leukemia (AML), relapsed or refractory, Acute lymphoblastic leukemia (ALL), relapsed or refractory.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}